Estrogen receptor-β status influences clinical outcome of triple-negative breast cancer

Breast Cancer

Volumn 16, Issue 4, 2009, Pages 281-282

  Sakamoto, Goi ^a   Honma, Naoko ^b,c  

^a Academy of Breast Pathology   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c CANCER INSTITUTE   (Japan)

Author keywords

Estrogen receptor ; Triple negative breast cancer

Indexed keywords

ESTROGEN RECEPTOR BETA; TAMOXIFEN;

BREAST CANCER; CONFERENCE PAPER; DISEASE FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

BREAST NEOPLASMS; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 70349653456     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0110-3     Document Type: Conference Paper

References (2)

1. N Honma R Horii T Iwase S Saji M Younes K Takubo M Matsuura Y Ito F Akiyama G Sakamoto 2008 Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy J Clin Oncol 26 3727 3734 18669459 10.1200/JCO.2007.14.2968
2. N Honma S Saji R Kurabayashi J Aida T Arai R Horii F Akiyama T Iwase N Harada M Younes M Toi K Takubo G Sakamoto 2008 Oestrogen receptor-β1 but not oestrogen receptor-βcx is of prognostic value in apocrine carcinoma of the breast APMIS 116 923 930 19132986 10.1111/j.1600-0463.2008.01122.x